Merck inks Keytruda deal with Surface Oncology; Rocket Pharmaceuticals gets expedited review of gene therapy for rare pediatric disease
Merck’s cash cow Keytruda has found another partner.
The pharma took the wraps off a collaboration deal on Tuesday to pair Keytruda with Surface Oncology’s IL-27 targeting antibody SRF388. The combo will be studied as a component of Surface’s Phase I study for SRF388 in patients with solid tumors, specifically those with liver and kidney cancer.
Surface has identified specific tumor types in which it believes IL-27 plays a role in resistance to checkpoint inhibitors. The company says it got the initial Phase I results it was looking for back in November, and is now headed into the expansion stage of the study. The initial results are expected to be read out in the first half of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
